Back to results
US 2026/0216245 A1Published application
Therapeutic base editing
AssigneesThe J. David Gladstone Institute, A Testamentary Trust Established Under the Will of J. David Gladst, The Regents of the University of California
InventorsAlexander Marson, Carl Ward, Ralf Schmidt
Life of this patent
Estimating the term…
Abstract
A method to screen for base edited genes with modifications in therapeutic targets, cells produced by the method and methods of using the modified cells are provided.
Claims31
A method comprising:
- contacting human immune cells with one or more sgRNAs targeted to one or more coding regions in one or more genes and a base editor or nucleic acid encoding the base editor;
- and
- selecting one or more human immune cells that have an altered immune cell activity and optionally sorting the immune cells based on the profile.
(canceled)
(canceled)
An isolated cell having a base edited gene in FIG. 1, 2, 3, 4 or 7 which alters one or more activities of the cell.
(canceled)
-26. (canceled)
-30. (canceled)
-33. (canceled)
-36. (canceled)
Dependencies are inferred from the claim text.